An Open-Label, Phase II Trial of Patupilone (EPO906) as Monotherapy to Evaluate Activity of Patupilone in Patients With Advanced Unresectable and/or Metastatic Hepatocellular Carcinoma (HCC).

Trial Profile

An Open-Label, Phase II Trial of Patupilone (EPO906) as Monotherapy to Evaluate Activity of Patupilone in Patients With Advanced Unresectable and/or Metastatic Hepatocellular Carcinoma (HCC).

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Patupilone (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 05 Apr 2012 Actual patient number changed from 65 to 25 as reported by ClinicalTrials.gov.
    • 24 Mar 2011 Actual end date (Oct 2006) added as reported by ClinicalTrials.gov.
    • 22 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top